HIV-1 Immunogen Design for Broadly Neutralizing Antibody Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccine development faces challenges in inducing broadly neutralizing antibodies (BnAbs) due to difficulties in identifying envelope proteins that bind with high affinity to the germline or unmutated common ancestors, particularly for CD4 binding site BnAbs, and understanding the interplay between virus evolution and antibody maturation in early infection.
Innovation Solution
The development of HIV-1 immunogens comprising specific envelope protein constructs, such as gp120 CD4 binding site loop regions, and nucleotide sequences encoding these proteins, administered through various vectors and regimens to induce immune responses and trigger the production of BnAbs, leveraging the CH103 CD4bs BnAb lineage as a model for vaccine design.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If heterologous Envs are used to induce BnAbs, then neutralization breadth may be improved, but binding affinity to unmutated common ancestors (UCAs) is lost
Solution Approach 1:
The patent applies preliminary action by first identifying and characterizing the UCAs of CD4bs BnAbs before designing immunogens. Env sequences are selected and engineered to specifically bind these UCAs with high affinity, establishing the correct starting point for antibody maturation. This preliminary binding ensures that the immune response is directed toward the desired BnAb lineage from the outset, rather than attempting to induce breadth without proper initial targeting.
Solution Approach 2:
The patent employs parameter changes by modifying Env protein sequences to optimize their binding properties. Specifically, Env sequences are engineered to maintain or enhance affinity for UCAs while incorporating features that promote broad neutralization. The patent also involves changing the structural parameters of immunogens (such as glycan composition and conformational stability) to better mimic the native viral envelope and elicit the desired antibody response.
2Productivity
If Envs are selected to bind with high affinity to UCAs, then induction of BnAbs may be improved, but the complexity of identifying suitable Envs increases
Solution Approach 1:
The patent applies copying by creating simplified models and representations of the complex Env-UCAs interaction. Phylogenetic analysis copies evolutionary information from natural viral sequences to identify conserved regions. Computational models copy and simulate binding interactions to predict which Envs will bind UCAs with high affinity, reducing the need for extensive experimental screening.
Solution Approach 2:
The patent uses intermediaries to bridge the gap between UCAs and heterologous Envs. Engineered immunogens serve as intermediaries that combine features of both - they maintain the conserved epitope structures recognized by UCAs while incorporating elements from heterologous Envs that promote broad neutralization. This intermediary approach simplifies the identification process by providing a defined set of candidate immunogens with predicted dual functionality.
3Reliability
If sequential immunization with evolved Envs is performed, then B cell maturation pathways may be replicated, but the number of vaccination steps increases
Solution Approach 1:
The patent applies preliminary action by pre-designing and pre-characterizing a series of immunogens that correspond to different stages of antibody maturation. Rather than using sequential immunization with naturally evolved viruses, the desired evolutionary trajectory is prepared in advance. The first immunogen is selected to specifically target the UCA, and subsequent immunogens are pre-selected to guide maturation through predicted intermediate states, reducing the need for extensive sequential optimization.
Solution Approach 2:
The patent employs dynamics by making the immunization regimen adaptable and adjustable. Rather than following a fixed sequential protocol, the vaccine strategy allows for dynamic adjustment of immunogen selection based on the observed immune response. If maturation proceeds faster or slower than predicted, the timing and selection of subsequent immunogens can be optimized, allowing the system to adapt to actual B cell responses while still guiding them toward the desired BnAb outcome.
Data Source
AI summary
The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).